MedTrace Logo

Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema

NCT00900887 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2015-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of ocular topic antiinflammatory therapy (sodic nepafenac at 0.1% or ketorolac at 0.5%) to treat center point thickness secondary to selective photocoagulation in diabetics with clinically significant macular edema.

Conditions

Interventions

DRUG

Ketorolac

ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week

DRUG

Nepafenac

topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week

DRUG

Polietilenglicol 400, propilenglicol

ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week

Sponsors & Collaborators

  • Hospital Juarez de Mexico

    lead OTHER_GOV

Principal Investigators

  • Virgilio Lima Gomez, MD, MSc · Hospital Juarez de Mexico

  • Dulce M Razo Blanco Hernandez, MD · Hospital Juarez de Mexico

  • Juan Asbun Bojalil, MD, PhD · Hospital Juarez de Mexico

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900887 on ClinicalTrials.gov